FOLH1 and prostate carcinoma: On 1 December 2020, almost 10 years after its discovery, [68Ga]Ga-PSMA-11 was approved by the Food and Drug Administration (FDA) [1] as the first 68Ga-labeled radiopharmaceutical for PET imaging of PSMA-positive prostate cancer.